Evidence map›Paper›PMID 37549552›Full record

ArticleJournal of pharmaceutical and biomedical analysis2023

An LC-ESI-MS/MS method for determination of ondansetron in low-volume plasma and cerebrospinal fluid: Method development, validation, and clinical application.

Anna Siemiątkowska, Karen Frey, Katharine N Gurba, Lara W Crock, Simon Haroutounian, Leonid Kagan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Bioanalytical considerations for quantification of ondansetron in rat microdialysis study using LC-MS/MS.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Anna SiemiątkowskaDepartment of Pharmaceutics and Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA; Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland. Electronic address: asiemiatkowska@ump.edu.pl.
Karen FreyDepartment of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: freyk@wustl.edu.
Katharine N GurbaDepartment of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: gurbak@wustl.edu.
Lara W CrockDepartment of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: crockl@wustl.edu.
Simon HaroutounianDepartment of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: sharout@wustl.edu.
Leonid KaganDepartment of Pharmaceutics and Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA. Electronic address: lkagan@pharmacy.rutgers.edu.
Washington University in St. Louis · USRutgers, The State University of New Jersey · USUniversity of Washington · US

Funding

5-HT3 receptor antagonists for neuropathic painR01NS104500 · NINDS · WASHINGTON UNIVERSITY · PI HAROUTOUNIAN, SIMON · 2018 to 2022
$2.2M
NINDS NIH HHS R01 NS104500
6 · The paper itself

Abstract

Ondansetron is used in clinical settings as an antiemetic drug. Although the animal studies showed its potential effectiveness also in treating neuropathic pain, the results from humans are inconclusive. The lack of efficacy of ondansetron in a subset of patients might be due to the overexpression of P-glycoprotein, which could result in low concentrations of ondansetron in the central nervous system (CNS). A surrogate of the CNS exposure might be drug concentration in the cerebrospinal fluid (CSF), especially in humans, as assessing the drug disposition directly in the patient's brain would be challenging. The study aimed to develop a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine concentrations of ondansetron in human K

Indexed as

OndansetronTandem Mass SpectrometryAnimalsChromatography, LiquidHumansPilot ProjectsReproducibility of ResultsOndansetron5-HT3 receptor antagonistAssay validationBlank matricesCarry-overMethods comparisonP-glycoprotein

Identifiers

PMID37549552
PMCPMC10529361
OpenAlexW4385496775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.